Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
adenovirus type 5 vector
- Development stage
- Approved
- Lead developer
- CanSino Biologics
- Modality
- Gene Therapies, Vaccines & Immunotherapeutics
- Administration
- Inhalation
01
Overview
An inhaled recombinant adenovirus type 5 (Ad5) vector-based vaccine candidate developed by CanSino Biologics for the prevention of tuberculosis. The vaccine utilizes a replication-deficient Ad5 vector to deliver Mycobacterium tuberculosis antigens, specifically the Ag85A protein, directly to the respiratory mucosa. This delivery method is intended to stimulate mucosal immunity in the lungs, providing a more targeted defense against M. tuberculosis infection compared to systemic vaccination. It is primarily being evaluated as a booster for individuals who have previously received the Bacillus Calmette-Guérin (BCG) vaccine. The candidate is currently in Phase 1 clinical development.
- Other names
- Inhaled Tuberculosis Vaccine (Adenovirus Type 5 Vector)Ad5-Ag85AAd-5-Ag85AAd 5-Ag85ARecombinant Adenovirus Type 5 Vector Tuberculosis Vaccine
02
Targets
Ag85A (Antigen 85A)CXADR (Coxsackievirus and adenovirus receptor)Neuraminidase
Beyond the preview
Go deeper on adenovirus type 5 vector.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on adenovirus type 5 vector.